Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis, page-47

First 47 Last

Share
Profile

Follow
NZ Trader

13,454 Posts.

7282

20/12/24

08:09

Post #: 77134057
Share

Originally posted by pinch2020: ↑

https://www.fiercepharma.com/pharma/novartis-shutter-2-morphosys-sites-lay-330-staffers-post-buyout-consolidation

Not looking great for pelabresib....OUCH!

A perfect storm is brewing for Syntara. The $2.9 billion US purchase by Novarits just shows you how desperate some of the big players are to keep a large piece of the market with Jafaki patents expiring in 2028.

My money is still on BMS. They have their own patent issues, roughly 60% of their revenue is heading to the patent cliff.

https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade

Here's some of their big drugs with patents expiring in the short term.

Revlimid- 2025-2026
Eliquis- 2027-2029
Opdivo- 2028

https://www.livewiremarkets.com/wires/61584

Frazis interview up on livewire.

Syntara shareholders own 100% of the drugs that we have in the clinic. It only becomes apparent at the end stage, when the amount of life left on a patent has a huge impact on value.

The number of times I've sat there with big pharma companies and they look at you across the table and they sort of tense up and they say, how much patent is left?

They’re expecting a bad number, and are pleasantly pleasant relieved when they hear how much we’ve got. Because for them, every extra year of life on a patent adds a huge amount to the net present value of the of the asset, and allows both us and them internally to argue for a higher price.

Here's another part of the interview that caught my attention.

One of them is in low risk MDS, the other one's in high risk.

So 12 months from now, some suggestion of efficacy in those two diseases will, I think, more than double the value of the drug to a big pharma company.

Expand

Market Cap under $100m with 4 Phase II Candidates ,, With further data expected in March we can expect an increase in SH value plus we may all be pleasantly surprised with the addition of a Partner to assist with Funding and gaining a cornerstone position to establish a relationship with SNT to see off and deter any other suitors ,, exciting times ahead ... looking forward to 2025 here at SNT.. NZT

Would be great to have Christmas with SNT holding 7c ..... nice Christmas Present for us all ...

SNT Price at posting: 6.4¢ Sentiment: Buy Disclosure: Held
20 Upvote

0 Great analysis

Reply

Top Stories

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

RCE

Recce locks in $30M to boost commercialisation across ASEAN region

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

First 47 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 5.8¢		Change 0.001(1.75%)		Mkt cap ! $94.23M

Open	High	Low	Value	Volume
5.6¢	6.0¢	5.6¢	$217.9K	3.795M

Buyers (Bids)

No.	Vol.	Price($)
2	272985	5.7¢

Sellers (Offers)

Price($)	Vol.	No.
5.8¢	32000	1

View Market Depth

No.	Vol.	Price($)
2	272985	0.057
1	90000	0.056
6	211083	0.055
2	28908	0.054
5	465571	0.053

Price($)	Vol.	No.
0.059	500336	2
0.060	127904	1
0.061	190000	2
0.062	150000	2
0.063	225100	2

Last trade - 16.10pm 17/06/2025 (20 minute delay)

SNT (ASX) Chart

Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis, page-47

Many are concerned about global falling birthrates. This diverse stock has solutions

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Recce locks in $30M to boost commercialisation across ASEAN region

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis, page-47

Top Stories

Many are concerned about global falling birthrates. This diverse stock has solutions

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Recce locks in $30M to boost commercialisation across ASEAN region

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News